on MAS.)
On the flip side, I can bring an understanding of, and comfort with, newer medications, which typically receive U.S. Food & Drug Administration approval in adults first, to my pediatric practice, and I can serve as a resource to pediatric colleagues who are looking to begin to use these medications for pediatric patients. With regard to research, it is nice to have access to colleagues, grant opportunities, research communities and other resources on both sides. What would you say to a medical student or resident considering a career in Med-Peds rheumatology?
Dr. Sadun: I am so glad that I pursued the combined training. I love being able to draw on things I’ve learned in one context and apply it to the other—and I love being able to care for patients of all ages, especially when I can offer multigenerational care and when I can care for a patient as they are transitioning from the pediatric world to adult rheumatology care. It’s a joy and an honor to be part of big transitions in people’s lives, and it’s an incredible privilege not to have to say goodbye to your patients when they reach a certain age.
In Sum
Med-Peds rheumatologists are board certified in both adult and pediatric rheumatology. Their dual training affords them unique perspectives in clinical practice as well as research. Trainees interested in pursuing a career in Med-Peds rheumatology or program leaders interested in training a Med-Peds rheumatology fellow can reach out to Dr. Nigrovic or the author.
Sarah D. Bayefsky, MD, is a fourth-year adult and pediatric rheumatology fellow at the University of Pennsylvania, Philadelphia, and Children’s Hospital of Philadelphia.
